Ellex to Boost Production of iTrack Microcatheters to 50 Thousand a Year

September 8, 2017: By Jon Swedien
Ellex iTrack microcatheter

Ellex iTrack microcatheter

Ellex Medical Lasers Limited will increase the production of its iTrack canaloplasty microcatheter from 20 thousand annually to 50 thousand, the Australian company announced Sept. 4.

The company is expanding and upgrading its manufacturing facility in Fremont, California. Ellex plans to complete the expansion by July 2018.

In July, Ellex increased production capacity at the Fremont site to 20 thousand units per year from 10 thousand, the company said.

Ellex said it sold about 10 thousand iTrack devices in its 2017 fiscal year that ended June 30.

Meanwhile, Ellex said it has already begun planning for a third production increase that would enable the plant to produce upward of 100 thousand units per year.

In December 2016, the company sold shares to raise $10.3 million to support sales of the iTrack in the US and China.

The Centers for Medicare and Medicaid Services in November 2016 increased the reimbursement available to ASCs purchasing and using the iTrack to $1,747 per procedure in 2017, up from $976 in 2016.

In canaloplasty, the iTrack is inserted into Schlemm’s canal, where it can open or dilate the full 360 degrees of Schlemm’s canal.

Ellex acquired the iTrack in 2014.

Headquartered in Adelaide, Australia, Ellex offers ophthalmic lasers and devices to treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, and age-related macular degeneration.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel to Review Aerie’s Rhopressa in October

Johnson & Johnson Vision Acquires Online Contact Lens Business Sightbox

Novartis Returns OUS Rights for Jetrea to ThromboGenics

Eyevance Licenses Zerviate from Nicox for US Commercialization

Two Eye Projects Fail to Make Final Round for $100M Grant

Ophthotech Begins Phase IIa Trial for Zimura in Wet AMD

Graybug Vision Begins Phase I/II Trial for Candidate in Wet AMD

BioTime Receives $1.56 Million NIH Grant to Advance OpRegen for Dry AMD

FDA Approves Mvasi, a Biosimilar of Avastin Co-developed by Amgen, Allergan

Carl Zeiss Meditec Launches Zeiss Clarus 500 Ultra-Widefield Fundus Imaging System in US

Imprimis Appeals to Public Sentiment in Fiery Response to Allergan Lawsuit

Roche’s Lampalizumab Fails in Phase III Study in Geographic Atrophy

Aldeyra Reports Positive Phase IIa Results for Dry Eye Candidate ADX-102

US Denies Coherus’ Petitions Challenging AbbVie’s Patent for Humira

Ocular Therapeutix Names Michael Goldstein, MD, Chief Medical Officer

PhysIOL Agrees to Acquire Majority Stake in Italian Optikon

Rayner Creates US Subsidiary in New York

Inotek to Merge with Gene Therapy Startup Rocket

Allergan Agrees to $13.75 Million Deal with Tribe to Protect Restasis Patents

Ellex to Boost Production of iTrack Microcatheters to 50 Thousand a Year

Coming soon

2017 Retinal Pharmaceuticals and Biologics Report: A Global Market Analysis for 2016 to 2022